University Hospital of Parma

University Hospital of Parma

SEARCH FILTERS
Time filter
Source Type

"Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some - but not all - patients with non-small cell lung cancer (NSCLC)," said Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. "Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond." He continued: "PD-L1 expression in a biopsy of tumour tissue is now used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of immune response." This study assessed the ability of white blood cell counts to predict whether lung cancer patients responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days. The researchers found that white blood cell counts at baseline and during therapy did predict whether lung cancer patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment. ESMO is the leading professional organisation for medical oncology, with over 15,000 members representing oncology professionals from over 130 countries worldwide.


"Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some - but not all - patients with non-small cell lung cancer (NSCLC)," said Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. "Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond." He continued: "PD-L1 expression in a biopsy of tumour tissue is now used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of immune response." This study assessed the ability of white blood cell counts to predict whether lung cancer patients responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days. The researchers found that white blood cell counts at baseline and during therapy did predict whether lung cancer patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment. ESMO is the leading professional organisation for medical oncology, with over 15,000 members representing oncology professionals from over 130 countries worldwide.


News Article | May 4, 2017
Site: www.eurekalert.org

Geneva, Switzerland, 05 May 2017 - White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).1 "Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some - but not all - patients with non-small cell lung cancer (NSCLC)," said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. "Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond." He continued: "PD-L1 expression in a biopsy of tumour tissue is used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of immune response." This study assessed the ability of white blood cell counts to predict whether lung cancer patients responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days. White blood cell counts were performed at baseline, after two nivolumab cycles, and after four nivolumab cycles. The researchers compared white blood cell counts between responders and non-responders to nivolumab. The researchers found that white blood cell counts at baseline and during therapy predicted whether patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment. Responders to nivolumab also had a greater number and concentration of CD8 positive T cells that expressed PD-1. Tiseo said: "The number and function of natural killer cells and the frequency of PD-1 expression in CD8 positive T cells could be predictive biomarkers for nivolumab treatment in advanced NSCLC. The identification of a panel of blood predictive biomarkers would enable the early identification of patients most likely to benefit from anti-PD-1 and anti-PD-L1 treatment." Commenting on the findings, Dr Stefan Zimmermann, Senior Consultant, Medical Oncology Department, HFR - Hôpital Cantonal, Fribourg, Switzerland, said: "In the current era of precision medicine and increasing healthcare costs we urgently need proper predictive biomarkers to select patients that will benefit from a specific therapy." He continued: "This study found that baseline levels of certain white blood cells do have a role in predicting response to immunotherapy in patients with lung cancer. These new factors should be investigated in future clinical trials, together with tumour PD-L1 expression and other markers that constitute the cancer immunogram predict whether or not patients will benefit from treatment." 1 Abstract 30PD - 'Circulating immune-profile as predictor of outcome in NSCLC patients treated with Nivolumab' will be presented by Dr Marcello Tiseo during the Poster Discussion session 'Epidemiology and innovations in biomarker development' on Saturday, 6 May, 16:45 (CEST). This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO or IASLC who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct. The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancers. It is organised by the European Society for Medical Oncology and the International Association for the Study of Lung Cancer in partnership with ESTRO and ETOP. ELCC provides a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2,000 attendees are expected from throughout Europe and the rest of the world. ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment. http://www. The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www. for more information.


PubMed | University Hospital of Parma and Istituti Ospitalieri di Cremona
Type: Journal Article | Journal: Oncology reviews | Year: 2015

Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy, although there is evidence of efficacy of adjuvant use of vaccine among all the strategies used. This article aims to collect published experiences with systemic adjuvant approaches in RCC and to describe the results of past and ongoing phase III clinical trials in this field. We explored all the systemic treatments, including chemotherapy, immunotherapy and targeted drugs while alternative approaches have also been described. Appropriate selection of patients who would benefit from adjuvant therapies remains a crucial dilemma. Although the international guidelines do not actually recommend any adjuvant treatment after radical surgery for RCC, no conclusions have yet been drawn pending the results of the promising ongoing clinical trials with the target therapies. The significant changes that these new drugs have made on advanced disease outcome could represent the key to innovation in terms of preventing recurrence, delaying relapse and prolonging survival after radical surgery for RCC.

Loading University Hospital of Parma collaborators
Loading University Hospital of Parma collaborators